Extract

1Women's and Children's Hospital, Adelaide, Australia; 2Kitasato University School of Medicine, Kanagawa; 3Nagasaki University School of Medicine, Nagasaki; 4Teikyo University School of Medicine, Tokyo, Japan; 5The JONES Group/JMI Laboratories, North Liberty, IA, USA

Sir,

Peptide deformylase (PDF) has been recognized as a new target for antibacterial agents and several PDF inhibitors have been developed.1 LBM415 (NVP PDF-713) is a new PDF inhibitor with documented activities against Gram-positive organisms.2–5 The aim of this study was to evaluate the potency of LBM415 against key Gram-positive pathogens, as well as Haemophilus influenzae, from Japan where antimicrobial resistance levels are very high among clinically significant Gram-positive organisms and community-acquired respiratory pathogens.6,7

A total of 695 clinical isolates originally collected in Japan included Staphylococcus aureus (n=222), Haemophilus influenzae (n=119), Streptococcus pneumoniae (n=122), coagulase-negative staphylococci (CoNS; n=119), Enterococcus spp. (n=65) and Streptococcus spp. (n=48). No vancomycin-resistant enterococci were detected during this period. LBM415 (Novartis Pharmaceuticals, Basel, Switzerland) was diluted in broth microdilution trays or agar using NCCLS methods and media supplements as required.8 NCCLS quality control strains with established MIC ranges were included throughout the study.

You do not currently have access to this article.